- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.03. | Nasdaq Stockholm AB: Amniotics AB (publ) receives observation status | 194 | GlobeNewswire | On March 21, 2024, Amniotics AB (publ) (the "Company") disclosed a press
release with information on the Company's financial situation.
Today, on March 22, 2024, Magle Chemoswed Holding AB disclosed... ► Artikel lesen | |
| 22.11.23 | Nasdaq Stockholm AB: New equity right for trading, Amniotics AB TO3 (597/23) | 320 | GlobeNewswire | At the request of Amniotics AB, Amniotics equity rights will be traded on First
North Growth Market as from November 24, 2023.
Security name: Amniotics option rights TO 3
--------------------------------------------
Short... ► Artikel lesen | |
| 17.11.23 | Nasdaq Stockholm AB: Last day of trading in paid subscription units (BTU) of Amniotics AB (585/23) | 278 | GlobeNewswire | Trading in Amniotics AB paid subscription units is to cease. The last trading
day is November 20, 2023.
Short name: AMNI BTU
---------------------------
ISIN code: SE0020848422
---------------------------
Orderbook... ► Artikel lesen | |
| 10.10.23 | Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Amniotics AB (522/23) | 492 | GlobeNewswire | With effect from October 11, 2023, the unit rights in Amniotics AB will be
traded on First North Growth Market. Trading will continue up until and
including October 20, 2023.
Instrument: Unit... ► Artikel lesen | |
| 05.10.23 | XFRA CAPITAL ADJUSTMENT INFORMATION - 05.10.2023 | 765 | Xetra Newsboard | Das Instrument 5N91 AU000000AGR4 AGUIA RES LTD AD-,20 EQUITY wird cum Kapitalmassnahme gehandelt am 05.10.2023 und ex Kapitalmassnahme am 06.10.2023 The instrument 5N91 AU000000AGR4 AGUIA RES LTD AD-... ► Artikel lesen |
5 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 9,895 | +1,59 % | Evotec nach dem Horror-Crash - war's das? | Die Kursentwicklung des einstigen deutschen Biotech-Vorzeige-Unternehmens Evotec in den vergangenen Monaten gleicht einem Trauerspiel. Notierte die Aktie vor knapp einem Jahr noch über 24 Euro, so ist... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 878,20 | +5,20 % | Regeneron Pharmaceuticals Q1 Profit Decreases, misses estimates | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) reported a profit for first quarter that decreased from the same period last year and missed the Street estimates.The company's earnings... ► Artikel lesen | |
| BRAIN BIOTECH | 2,820 | +0,71 % | EQS-News: BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur | EQS-News: BRAIN Biotech AG
/ Schlagwort(e): Sonstiges
BRAIN Biotech AG unternimmt nächsten Schritt zur Optimierung der Gruppenstruktur
16.04.2024 / 11:20 CET/CEST
Für... ► Artikel lesen | |
| SCORPIUS | 0,175 | -3,85 % | Scorpius Holdings, Inc.: Scorpius Holdings Provides 2023 Year-End Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023 | DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ('Scorpius" or "the Company"), an integrated contract development and manufacturing organization providing... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,872 | -0,43 % | Impulse setzen - Cardiol Therapeutics, Evotec, Redcare Pharmacy Aktie | Für risikobewusste Anleger ist die Pharma- und Biotechsparte ein lukrativer Markt für Investitionen. Die Branche wächst seit Jahrzehnten und auch für die kommenden Jahre wird mit einem Wachstum von... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 0,236 | +27,22 % | Burcon NutraScience Corporation: HPS and Burcon Achieve First Commercial Sales of World's First Hemp Protein Isolate | Vancouver, British Columbia--(Newsfile Corp. - April 29, 2024) - Burcon NutraScience Corporation (TSX: BU) ("Burcon" or the "Company"), a global technology leader in the development of plant-based... ► Artikel lesen | |
| CSL | 167,82 | +0,66 % | CSL: Real-World Evidence Study Proves Effectiveness Of Cell-Based Quadrivalent Influenza Vaccines | CANBERA (dpa-AFX) - CSL Seqirus, a subsidiary of CSL Ltd. (CSL.AX), Thursday said that a real-world evidence study shows that a cell-based quadrivalent influenza vaccine has been more effective... ► Artikel lesen | |
| MANNKIND | 4,043 | +4,85 % | MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases | First-in-human study to evaluate safety, tolerability and pharmacokinetics (PK) in healthy volunteersEnrollment of first study participant anticipated in June 2024 DANBURY, Conn. and WESTLAKE VILLAGE... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 5,360 | +20,80 % | Ocular Therapeutix, Inc.: Ocular Therapeutix to Host Investor Day in New York City on Thursday, June 13, 2024 | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,264 | +9,34 % | Oxford Nanopore Tech - Issue of Equity and Total Voting Rights | ||
| CODEXIS | 2,970 | +8,79 % | CODEXIS, INC. - 10-Q, Quarterly Report | ||
| ADAPTIMMUNE THERAPEUTICS | 1,100 | -0,90 % | Adaptimmune Therapeutics PLC: Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024 | Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell... ► Artikel lesen | |
| BIORA THERAPEUTICS | 0,665 | +8,13 % | Biora Therapeutics, Inc.: Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development | All pharmacokinetic endpoints were achieved, with a PK profile consistent with drug delivery and absorption in the colon All NaviCap devices performed as intended and were well tolerated, with... ► Artikel lesen | |
| TELO GENOMICS | 0,121 | +22,84 % | Telo Genomics Corp.: Telo Genomics Receives Accreditation from College of American Pathologists | Toronto, Ontario--(Newsfile Corp. - April 10, 2024) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology... ► Artikel lesen | |
| CORMEDIX | 5,200 | +5,69 % | CorMedix, Inc.: CorMedix Inc. Announces CMS Grants TDAPA to DefenCath | BERKELEY HEIGHTS, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening... ► Artikel lesen |
Das Unternehmen AMNIOTICS AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
